List of Excipients in Branded Drug VOCABRIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ViiV Healthcare Company	VOCABRIA	cabotegravir sodium	49702-248	CELLULOSE, MICROCRYSTALLINE	2026-01-21
ViiV Healthcare Company	VOCABRIA	cabotegravir sodium	49702-248	HYPROMELLOSE	2026-01-21
ViiV Healthcare Company	VOCABRIA	cabotegravir sodium	49702-248	LACTOSE MONOHYDRATE	2026-01-21
ViiV Healthcare Company	VOCABRIA	cabotegravir sodium	49702-248	MAGNESIUM STEARATE	2026-01-21
ViiV Healthcare Company	VOCABRIA	cabotegravir sodium	49702-248	POLYETHYLENE GLYCOL	2026-01-21
ViiV Healthcare Company	VOCABRIA	cabotegravir sodium	49702-248	SODIUM STARCH GLYCOLATE TYPE A CORN	2026-01-21
ViiV Healthcare Company	VOCABRIA	cabotegravir sodium	49702-248	TITANIUM DIOXIDE	2026-01-21

Vocabria Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Vocabria is the oral cabotegravir tablet marketed by ViiV Healthcare as part of the Cabenuva regimen for HIV-1 treatment. Its excipient strategy is commercially conservative: a conventional immediate-release film-coated tablet supports rapid oral exposure, manufacturing scale, and temporary use as an oral lead-in or bridging therapy. The largest excipient opportunities are not in copying the existing tablet, but in improving dissolution, reducing manufacturing cost, enabling alternative dosage forms, and supporting future long-acting cabotegravir products.

What is Vocabria and how is it used?

Vocabria contains cabotegravir, an integrase strand transfer inhibitor. The 30 mg tablet is used with rilpivirine injections in adults and adolescents weighing at least 35 kg who are virologically suppressed on a stable antiretroviral regimen and have no history of treatment failure or known resistance to cabotegravir or rilpivirine.[1]

Attribute	Vocabria profile
Active ingredient	Cabotegravir
Strength	30 mg tablet
Dosage form	Immediate-release, film-coated tablet
Sponsor	ViiV Healthcare
Therapeutic class	HIV-1 integrase strand transfer inhibitor
Companion product	Edurant oral rilpivirine and Cabenuva cabotegravir/rilpivirine injections
FDA approval	January 2021
Primary use	Oral lead-in before injections or oral bridging when an injection is delayed
Administration	Once daily when used as oral therapy
Food relationship	May be taken with or without food, according to labeling

Vocabria is not the main chronic oral cabotegravir product for most patients. Its commercial role is linked to long-acting Cabenuva, which uses oral cabotegravir during initiation or when injectable dosing cannot occur on schedule.

What excipients are used in Vocabria tablets?

The tablet uses standard pharmaceutical excipients associated with direct-compression or conventional granulation processes. Public product information identifies lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and film-coating components among the inactive ingredients.[1,2]

The excipient architecture has four functional objectives:

1. Provide tablet bulk for a relatively low-dose active ingredient.
2. Promote mechanical strength during manufacturing and packaging.
3. Support rapid disintegration and dissolution.
4. Provide a stable, swallowable film-coated dosage form.

Functional role of the principal excipients

Excipient class	Likely function in Vocabria
Lactose monohydrate	Diluent and compression aid
Microcrystalline cellulose	Diluent, dry binder, and tablet-strength contributor
Sodium starch glycolate	Superdisintegrant
Hypromellose	Binder or film-forming polymer
Magnesium stearate	Lubricant
Film-coating pigments and plasticizers	Appearance, protection, swallowability, and handling

The combination is commercially important because it avoids a complex enabling formulation. A generic manufacturer would likely prioritize excipient equivalence, dissolution matching, impurity control, and process robustness over a novel delivery platform.

What formulation challenges affect cabotegravir excipient selection?

Cabotegravir has limited aqueous solubility. Its long-acting injectable formulation uses a nanosuspension approach to maintain drug exposure over an extended dosing interval. The oral tablet has a different technical requirement: it must deliver reproducible absorption rapidly enough to support oral lead-in and bridging use.

The main formulation risks are:

• Slow or variable dissolution.
• Sensitivity to particle-size distribution.
• Lubricant overmixing, which can reduce tablet wettability.
• Compression variability at commercial scale.
• Moisture effects on disintegration and stability.
• Excipient incompatibility that increases degradation products.
• Food-related changes in exposure.
• Batch-to-batch variation in bioavailability.

Excipient optimization should therefore focus on dissolution performance rather than simply increasing tablet hardness or reducing tablet size.

High-value excipient development areas

Wetting and dissolution enhancement

Surfactants, wetting agents, co-milled excipients, and hydrophilic polymer systems could improve the dissolution rate of cabotegravir. The commercial value is highest if the technology maintains immediate release without increasing food dependence or creating a new regulatory burden.

Potential candidates include:

• Sodium lauryl sulfate at low concentrations.
• Poloxamers.
• Crospovidone-based disintegration systems.
• Copovidone or povidone as wetting and binding aids.
• Hydroxypropyl cellulose or hydroxypropyl-beta-cyclodextrin where justified by compatibility and dose efficiency.

Any substitution would need comparative dissolution, impurity, stability, and bioequivalence support. A technically superior excipient is not commercially attractive if it creates a new clinical bridge requirement.

Lubrication control

Magnesium stearate is widely used but can impair wetting when applied at excessive concentrations or mixed for too long. A generic product developer could create value through:

• Lower lubricant concentration.
• Controlled lubrication time.
• Alternative lubricants such as sodium stearyl fumarate.
• Better powder-flow engineering before compression.

This is a process opportunity rather than a likely standalone patent opportunity.

Disintegration and tablet robustness

A high-performing disintegrant system can reduce dissolution variability while preserving tablet strength. Crospovidone and croscarmellose sodium are potential alternatives to sodium starch glycolate, but substitution could change water uptake, swelling, and dissolution kinetics.

The target profile is a tablet that:

• Survives coating and distribution.
• Disintegrates rapidly across physiological pH.
• Resists humidity-related changes.
• Maintains dissolution after prolonged storage.

Taste and patient acceptability

Vocabria tablets are swallowed, not chewed or dispersed. Taste masking has limited value for the marketed dosage form, although it becomes relevant for pediatric, geriatric, dysphagia, or decentralized-care products. Film-coating systems that improve swallowability without increasing tablet mass could support lifecycle management.

What commercial opportunities exist for excipient suppliers?

The most credible opportunities are tied to formulation support, quality-by-design packages, and differentiated oral products.

1. Generic formulation supply

A future generic cabotegravir tablet would require excipient suppliers able to provide:

• Pharmaceutical-grade lactose and microcrystalline cellulose.
• Consistent superdisintegrant performance.
• Low-variability lubricants.
• Film-coating systems with color and opacity matching.
• Regulatory documentation for global markets.
• Extractables, leachables, elemental impurity, nitrosamine, and allergen packages.

Because Vocabria is a small-molecule tablet, excipient suppliers face conventional generic competition. Price, supply continuity, particle-size control, and compendial compliance will be more important than proprietary functionality alone.

2. Dissolution-enabling platforms

A supplier with a validated platform for poorly soluble weak acids or neutral molecules could offer a higher-value solution. The strongest commercial proposition would combine:

• Improved dissolution.
• No increase in dose.
• No major change in tablet size.
• Stable performance under accelerated conditions.
• Compatibility with direct compression.
• A demonstrated pathway to bioequivalence.

Spray-dried dispersions, nanocrystalline API, co-processed excipients, and polymeric wetting systems are possible approaches. Their value depends on whether the oral tablet remains an immediate-release product and whether the technology can be manufactured at the required scale.

3. Long-acting cabotegravir support

The larger commercial opportunity is the injectable product rather than the oral tablet. Cabotegravir extended-release injection relies on a nanosuspension and requires control of particle size, crystal form, sedimentation, syringeability, redispersibility, and injection-site tolerability.[3]

Relevant excipient opportunities include:

• Surfactants for nanosuspension stabilization.
• Buffer systems.
• Tonicity modifiers.
• Viscosity control agents.
• Container-closure compatibility materials.
• Low-particulate injectable excipients.
• Manufacturing aids that improve sterile filtration or aseptic processing.

The injectable product has a higher technical barrier than Vocabria tablets. A supplier that solves syringeability or long-term suspension stability may have stronger negotiating leverage than a conventional tablet excipient supplier.

4. Alternative oral dosage forms

Lifecycle opportunities could include:

• Smaller tablets.
• Orally disintegrating tablets.
• Sprinkle formulations.
• Pediatric dispersible tablets.
• Oral suspensions for patients unable to swallow tablets.
• Dose-flexible tablets for bridging protocols.

These products would need to preserve cabotegravir exposure and avoid confusion with the injectable dosing schedule. Commercial adoption would depend on the size of the eligible patient population and whether ViiV or a generic sponsor sees value in extending the oral product beyond its current bridging role.

When does Vocabria lose exclusivity?

FDA approval occurred in January 2021. If Vocabria received five-year new chemical entity exclusivity, that period would run to January 2026, subject to the specific FDA regulatory designation and any applicable pediatric or other extensions.[1,4]

Patent expiry may extend beyond regulatory exclusivity. The relevant protection can include:

• Cabotegravir compound patents.
• Salt, polymorph, or crystal-form patents.
• Oral formulation patents.
• Long-acting injectable formulation patents.
• Dosing and administration patents.
• Combination-treatment patents covering cabotegravir with rilpivirine.
• Manufacturing patents for nanosuspension production.

Patent expiry must be assessed by jurisdiction because U.S. patent-term adjustment, pediatric exclusivity, terminal disclaimers, supplementary protection certificates, and national filing dates can change the effective generic-entry date.

What is the Orange Book status of Vocabria?

Vocabria is an FDA-approved small-molecule drug and is eligible for Orange Book patent listing. The commercial relevance of the listing depends on which patents cover the approved tablet, method of use, or related cabotegravir products.

A generic applicant would evaluate:

Regulatory route	Commercial implication
ANDA with Paragraph IV certification	Allows a patent challenge before expiry
ANDA with Paragraph III certification	Defers approval until listed patent expiry
Section viii carve-out	May permit approval for non-patented uses
505(b)(2) application	Relevant for a materially different formulation or route
Paragraph IV litigation	May trigger a 30-month stay if the patent holder sues within the statutory period

The critical issue is whether listed patents cover the 30 mg oral tablet specifically or only injectable cabotegravir, dosing regimens, or combination use. A generic company could face different risks for the tablet and the Cabenuva injection.

Which companies are likely to challenge Vocabria?

The most likely challengers are established HIV generic manufacturers and diversified companies with experience in antiretroviral ANDAs. Potential participants in a competitive market could include Teva, Mylan/Viatris, Sandoz, Cipla, Sun Pharma, Dr. Reddy's, and Hetero, although a company’s interest would depend on patent timing, market size, manufacturing economics, and ViiV’s litigation posture.

The tablet market may attract fewer challengers than a high-volume chronic oral antiretroviral because Vocabria is tied to a specialized injectable regimen. Generic demand would depend on:

• Continued use of Cabenuva.
• Use of oral cabotegravir for bridging.
• Payer coverage.
• Prescriber acceptance.
• Whether ViiV maintains a branded oral supply strategy.
• Whether a generic can enter without infringing injectable or method-of-use patents.

What patent litigation and settlement risks affect Vocabria?

Patent litigation risk is likely to center on cabotegravir patent families and the broader Cabenuva portfolio rather than excipients alone. Formulation patents may claim particle size, stabilizer combinations, injectable concentration, or manufacturing conditions. Method-of-use patents may cover dosing intervals, oral lead-in, missed injection management, or combination treatment with rilpivirine.

Settlement agreements could include:

• A deferred generic entry date.
• A license for oral tablets but not injections.
• Restrictions on injectable or pediatric products.
• Authorized-generic supply provisions.
• Geographic limitations.
• Covenants tied to specific patent claims.

For excipient companies, the key risk is indirect. A formulation platform may be technically non-infringing but still become commercially unusable if it relies on a patented particle-engineering, coating, or manufacturing process.

How strong is the Vocabria patent estate?

The estate is strongest where it protects the cabotegravir molecule, long-acting nanosuspension, and dosing architecture. A conventional oral tablet has a lower technical barrier and is more susceptible to design-around strategies.

Protection layer	Relative strength
Cabotegravir active ingredient	High, subject to expiry
Long-acting injectable formulation	High
Injectable manufacturing process	Medium to high
Oral tablet composition	Medium
Standard excipient selection	Low to medium
Dosing and missed-injection methods	Medium
Combination use with rilpivirine	Medium
Alternative oral dosage forms	Potentially medium

Excipient patents are unlikely to be the principal barrier unless they claim a specific dissolution-enhancing composition, particle-size control system, or manufacturing process with commercial relevance.

How does Vocabria compare with competing HIV products?

Product	Active ingredient	Form	Primary commercial role
Vocabria	Cabotegravir	Oral tablet	Lead-in or bridging for Cabenuva
Cabenuva	Cabotegravir plus rilpivirine	Long-acting injection	Extended-interval HIV treatment
Tivicay	Dolutegravir	Oral tablet	Chronic oral integrase-inhibitor therapy
Triumeq	Dolutegravir, abacavir, lamivudine	Fixed-dose tablet	Complete oral regimen
Dovato	Dolutegravir, lamivudine	Fixed-dose tablet	Complete two-drug oral regimen
Rukobia	Fostemsavir	Oral tablet	Heavily treatment-experienced patients

Vocabria has lower standalone oral demand than Tivicay because its primary role is to support Cabenuva. Cabenuva creates a recurring need for oral cabotegravir during initiation, missed-dose management, and selected patient transitions.

What generic launch scenarios exist?

Three scenarios are commercially plausible.

Early tablet-only entry

A company could challenge oral-tablet patents while avoiding claims directed to the injectable product. This would produce a limited market focused on oral bridging and lead-in use.

Broad cabotegravir competition

A later entrant could pursue both oral and injectable products. This would require substantially greater investment, sterile manufacturing capability, nanosuspension know-how, and litigation tolerance.

Authorized-generic or licensed entry

ViiV could preserve injectable differentiation while licensing oral cabotegravir supply. This scenario would reduce litigation risk but limit independent excipient and formulation innovation.

What geographic markets offer the best opportunities?

The United States has the clearest ANDA framework and the strongest Orange Book-driven patent challenge process. Europe may offer opportunities through national validation, centralized regulatory procedures, and supplementary protection certificate analysis. Emerging markets may have earlier commercial access where patent enforcement or local filing coverage differs, but pricing pressure is greater.

For excipient suppliers, the most valuable geographic capabilities are:

• U.S. FDA drug-master-file support.
• European Pharmacopoeia compliance.
• ICH stability packages.
• Local regulatory representation.
• Supply-chain qualification in India, Europe, and North America.
• Documentation for lactose, animal-origin, allergen, and elemental impurity controls.

Key Takeaways

• Vocabria is a 30 mg immediate-release cabotegravir tablet used mainly for Cabenuva initiation and oral bridging.
• Its current excipient design is conventional and optimized for manufacturability, disintegration, and stability.
• The strongest tablet opportunities involve dissolution enhancement, lubricant control, co-processed excipients, and alternative oral dosage forms.
• The higher-value technical market is Cabenuva’s injectable nanosuspension, where stabilizer, particle-size, and syringeability technologies create stronger barriers.
• FDA regulatory exclusivity began with the January 2021 approval and may have reached or approached its five-year point in January 2026, subject to the applicable exclusivity designation.
• Generic risk depends on tablet-specific patents, method-of-use claims, injectable-product patents, and any Paragraph IV litigation.
• Conventional excipients alone are unlikely to create a durable market barrier. Process control, bioequivalence, regulatory documentation, and supply reliability will determine commercial success.

FAQs

Is Vocabria lactose-free?

Public product information identifies lactose monohydrate among the tablet excipients. This makes lactose status relevant for patients with severe lactose intolerance and for generic developers pursuing a lactose-free formulation.[1,2]

Can cabotegravir tablets be used instead of Cabenuva injections?

Vocabria is not a general substitute for the Cabenuva injection regimen. Its labeled role is oral lead-in or bridging in combination with rilpivirine under the approved treatment protocol.

Does Vocabria require a taste-masking excipient?

Not for its principal swallowed-tablet use. Taste masking becomes more relevant for orally disintegrating, dispersible, liquid, or pediatric formulations.

Are excipient patents likely to block a generic Vocabria tablet?

Standard excipient choices are unlikely to create the main barrier. Risk is higher for patented dissolution systems, particle-engineered cabotegravir, coating systems, or manufacturing processes.

Is the Cabenuva injectable formulation a larger excipient opportunity than Vocabria?

Yes. The injectable nanosuspension has more demanding requirements for particle-size control, suspension stability, redispersibility, syringeability, sterility, and injection-site performance.

References

1. U.S. Food and Drug Administration. (2024). Vocabria (cabotegravir) tablets: Prescribing information. FDA.

2. European Medicines Agency. (2024). Vocabria: Product information. EMA.

3. U.S. Food and Drug Administration. (2024). Cabenuva (cabotegravir and rilpivirine) extended-release injectable suspensions: Prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

6. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. ICH.

7. International Council for Harmonisation. (2009). Q9: Quality risk management. ICH.